Wiley Blackwell

SHERPA: Unknown

People

  1. Palomba
    Palomba
  2. Noy
    Noy
  3. Kumar
    Kumar
  4. Zelenetz
    Zelenetz
  5. Yahalom
    Yahalom
  6. Hamlin
    Hamlin
  7. Horwitz
    Horwitz
  8. Moskowitz
    Moskowitz
  9. Dogan
    Dogan
  10. Salles
    Salles

Groups

  1. Center for Hematologic Malignancies (31)
  2. Department of Medicine (31)
  3. Hematologic Malignancies, Division of (31)
  4. Lymphoma (31)
  5. Survivorship Research (16)
  6. Hematology-Oncology Fellows (14)
  7. Radiation Oncology, Department of (11)
  8. Sloan Kettering Institute Postdocs (11)
  9. Executive Committee, Center for Hematologic Malignancies (10)
  10. Epidemiology and Biostatistics (9)
Search Within
  1. "Maria Palomba"
Formats
  1. Meeting Abstract (30)
  2. Journal Article (1)
Groups
  1. Center for Hematologic Malignancies (31)
  2. Department of Medicine (31)
  3. Hematologic Malignancies, Division of (31)
  4. Lymphoma (31)
  5. Survivorship Research (16)
  6. Hematology-Oncology Fellows (14)

More Groups

People
  1. Maria Palomba (31)
  2. Ariela Noy (12)
  3. Andrew Zelenetz (11)
  4. Anita Kumar (11)
  5. David Straus (10)
  6. Joachim Yahalom (10)

More People

Years
  1. 2024 (1)
  2. 2023 (10)
  3. 2021 (2)
  4. 2019 (12)
  5. 2017 (6)
Publications
  1. Hematological Oncology (30)
  2. eJHaem (1)

Results (31)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy
    Journal Article

    Lamanna, N.; Tam, C. S.; Woyach, J. A.; Alencar, A. J.; Palomba, M. L.; Zinzani, P. L.; Flinn, I. W.; Fakhri, B.; Cohen, J. B.; Kontos, A.; more...
    eJHaem (2024)

    Fulltext@MSK | Save
  • TRANSCEND FL: Phase 2 study results of lisocabtagene maraleucel (LISO‐CEL) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL)
    Meeting Abstract

    Morschhauser, F.; Dahiya, S.; Palomba, M. L.; Garcia‐Sancho, A. M.; Reguera Ortega, J. L.; Kuruvilla, J.; Jager, U.; Cartron, G.; Izutsu, K.; Dreyling, M.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Lisocabtagene maraleucel (LISO‐CEL) in R/R MCL: Primary analysis results from the MCL cohort of the single-arm, multicenter, seamless design transcend NHL 001 study
    Meeting Abstract

    Wang, M.; Siddiqi, T.; Gordon, L. I.; Kamdar, M.; Lunning, M.; Hirayama, A. V.; Abramson, J. S.; Arnason, J.; Ghosh, N.; Mehta, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • A phase I study of split‐course bringing radiotherapy (SC‐BRT) prior to commercial CD19 CAR T‐cell therapies for patients with relapsed or refractory B‐cell lymphomas
    Meeting Abstract

    Imber, B. S.; Yahalom, J.; Palomba, M. L.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • A phase I study of CD19‐targeted 19(T2)28z1xx CAR T cells in adult patients with relapsed or refractory diffuse large B‐cell lymphoma
    Meeting Abstract

    Palomba, M. L.; Riviere, I.; Sikder, D. S.; Senechal, B.; Wang, X.; Cathcart, E. R.; Liotta, K.; Li, J.; Sellner, L.; Sadelain, M.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • CNS radiotherapy as bridging prior to CAR T‐cell therapy for hematologic malignancies
    Meeting Abstract

    Cederquist, G.; Hubbeling, H.; Tringale, K.; Shah, G.; Alarcon Tomas, A.; Shouval, R.; Hajj, C.; Fregonese, B.; Lee, J.; Dahi, P. B.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma
    Meeting Abstract

    Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Long‐term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A. M.; Noy, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Impact of response to systemic bridging therapy on clinical outcomes and cytokine profile in patients receiving CAR T‐cell therapy for aggressive B‐cell lymphoma
    Meeting Abstract

    Wills, B.; Shouval, R.; Flynn, J.; Devlin, S. M.; Shah, G. L.; Scordo, M.; Dahi, P. B.; Lin, R. J.; Imber, B.; Parascondola, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save